We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Device That Detects Cancer Cells Could Help Avoid Invasive Biopsy Surgeries

By LabMedica International staff writers
Posted on 28 Feb 2023

Cancer is a major contributor to illness and death, and those with suspected cancer may need surgery for a diagnosis, especially for liver, colon or kidney tumors. More...

Unfortunately, biopsies can be uncomfortable, costly, and increase the risk of complications due to surgery. To resolve this problem, researchers have created a new device that can detect and analyze cancer cells from blood samples. This could eliminate the need for a biopsy surgery, as well as allow doctors to monitor treatment progress more accurately.

Researchers from the University of Technology Sydney (UTS, Sydney, Australia) have developed the Static Droplet Microfluidic device, which can quickly detect tumor cells that have migrated away from a primary tumor and into the bloodstream. The device utilizes a distinctive metabolic signature of cancer to separate tumor cells from regular blood cells. After tumor cells are located with the device, they can then be studied genetically and molecularly to support diagnosis and classification of the cancer, allowing for more personalized treatment options.

Circulating tumor cells are a precursor of metastasis, which is responsible for approximately 90% of all cancer-related deaths. Studying these cells may offer greater understanding of the biology behind cancer metastasis, which can help in the development of new treatments. The current liquid biopsy solutions are slow, expensive, and require specialist operators, restricting their use in clinical settings. This new technology is designed to be integrated into research and clinical labs without needing expensive and complex equipment or a trained operator, making it practical and cost-effective for doctors to diagnose and monitor cancer patients.

“Managing cancer through the assessment of tumor cells in blood samples is far less invasive than taking tissue biopsies. It allows doctors to do repeat tests and monitor a patient’s response to treatment,” said Professor Majid Warkiani from the UTS School of Biomedical Engineering.

Related Links:
University of Technology Sydney 


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated PCR System
OnePCR
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.